Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency
Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency
复制标题
DOI：
10.1053/j.ajkd.2006.11.043
复制
发表时间：
2007-03-01
影响因子：
13.2
通讯作者：
Lindenfeld, JoAnn
中科院分区：
文献类型：
--
作者：
Chonchol, Michel;Cook, Thomas;Lindenfeld, JoAnn
背景：轻度慢性肾功能不全患者发生心血管疾病的一个潜在可改变的危险因素是血脂异常。很少有研究检查他汀类药物对肾功能不全患者的全因死亡率和主要冠状动脉事件的影响。方法：我们对4444例冠心病患者的降胆固醇随机试验进行了事后分析：斯堪的纳维亚辛伐他汀生存研究。在4444名参与者中，2314名（52.1%）患有轻度慢性肾功能不全，定义为肾小球滤过率低于75 mL/min/1.73 m(2)。
Background: A potentially modifiable risk factor for cardiovascular disease in patients with mild chronic renal insufficiency is dyslipidemia. Few studies examined the effects of statins on all-cause mortality and major coronary events in patients with renal dysfunction.Methods: We performed a post hoc analysis from the Randomized Trial of Cholesterol Lowering in 4,444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study. Of 4,444 participants, 2,314 (52.1%) had mild chronic renal insufficiency defined as an estimated glomerular filtration rate less than 75 mL/min/1.73 m(2) (